Human recombinant erythropoietin-a increases the efficacy of irradiation in preclinical model;A rekombináns humán erythropoietin-α fokozza a humán laphámrák sugárérzékenysé gét preklinikai modellben

Magyar Onkologia

Volumn 51, Issue 1, 2007, Pages 53-61

  Lövey, József ^a   Kenessey, István ^b   Rásó, Erzsébet ^b   Dobos, Judit ^b,d   Vágó, Ágnes ^c   Kásler, Miklós ^a   Futosi, Krisztina ^b   Döme, Balázs ^d   Tímár, József ^b   Tóvári, József ^a,b,e  

^a Sugárterápiás ^*  (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c Kozponti Laboratorium   (Hungary)

^d Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOSENSITIZING AGENT; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL; ANOXIA; ARTICLE; GENETICS; HUMAN; IRON DEFICIENCY ANEMIA; METABOLISM; MICROCIRCULATION; MOUSE; MOUSE MUTANT; POLYMERASE CHAIN REACTION; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANEMIA, HYPOCHROMIC; ANIMALS; ANOXIA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; EPOETIN ALFA; HEMATINICS; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, SCID; MICROCIRCULATION; POLYMERASE CHAIN REACTION; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34548272684     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565, 2001
2. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87:5978- 5982, 1990
3. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307:999-1007, 2003
4. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477- 1487, 2003
5. Blackwell KL, Kirkpatrik JP, Snyder SA, et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 63:6162- 6165, 2003
6. Blohmer JU, Wurschmidt U, Petry G. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high risk cervical cancer. Proc Am Soc Clin Oncol 22:447, 2003
7. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714, 2006
8. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91:2214- 2221, 2001
9. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia inducible factor 1. Mol Cell Biol 23:4604-4613, 1996
10. Garcia-Baross M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159, 2003
11. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
12. Hall EH. Ed. Radiobiology for the Radiologist, 4th ed. Philadelphia, PA, Lippincott, 1994
13. Harris AL. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47, 2002
14. Henke M, Laszing R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 36:1255-1260, 2003
15. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation and chemotherapy. Cancer Res 65:3643- 3655, 2005
16. Ishikawa H, Sakurai H, Hasegawa M, et al. Expression of hypoxia-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 60:513-521, 2004
17. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326-333, 2002
18. Kirkpatrick JP, Hardee ME, Snyder SA, et al. The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 165:192-201, 2006
19. LaMontagne KR, Butler J, Marshall DJ, et al. Recombinant epoetins do not stimulate tumor growth in erythro- poietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347-355, 2006
20. Laveys RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 174(Suppl 4):24-30, 1998
21. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459- 460, 2003
22. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21:169-180, 2003
23. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28:49-53, 2001
24. Lövey J, Lukits J, Remenár E, et al. Antiangiogenic effects of radiotherapy but not initial microvessel density predict survival in inoperable oropharyngeal squamous cell carcinoma. Strahlenther Onkol 182:149- 156, 2006
25. Ludwig H. rHuEPO and treatment outcomes: The preclinical experience. Oncologist 9:48-54, 2004
26. Marinaccio M, Mele E, Giotta F. Pretreatment normalization of mild anemia with epoetin alfa: Impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol 22:486, 2003
27. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98:5181-5186, 2001
28. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441, 2004
29. Molls M, Stadler P, Becker A, et al. Relevance of oxygen in radiation oncology. Mechanism of action, correlation to low hemoglobin levels. Strahlenther Onkol 74(Suppl 4):13-16, 1998
30. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293-297, 2001
31. Rades D, Tribius S, Yekebas EF, et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: Final results of a prospective observational study. Int J Radiat Oncol Biol Phys 65:549- 465, 2006
32. Reichel O, Panzer M, Wimmer Ch, et al. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiotherapy for head and neck tumors. Eur Arch Otorhinolaryngol 260:248- 253, 2003
33. Ribatti D, Marzullo A, Nico B, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636, 1999
34. Scott SD, Greco O. Radiation and hypoxia inducible gene therapy system. Cancer Metastasis Rev 23:269-276, 2004
35. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 84:997-1004, 1994
36. Stasi R, Amadori S, Littlewood TJ, et al. Management of cancer-related anemia with erythropoietic agents: Doubts, certainties, and concerns. Oncologist 10:539- 554, 2005
37. Stüben G, Pöttgen C, Knuhmann K, et al. Erythropoietin restores the anaemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 55:1358-1362, 2003
38. Tchekmedyian NS. Anaemia in cancer patients: Significance, epidemiology, and current therapy. Oncology 1:17-24, 2002
39. Temkin SM, Hellmann M, Serur E, et al. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 16:1855- 1861, 2006
40. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61:1358- 1361, 2001
41. Tóvári J, Gilly R, Rásó E, et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels improving chemotherapy in human xenograft models. Cancer Res 65:7186-7193, 2005
42. Vaupel P, Kelleher DK, Höckel M. Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29-35, 2001
43. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Med Oncol 18:243-259, 2001
44. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin- 1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
45. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836- 843, 2001
46. Zips D, Eichler W, Geyer P, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 65:5374-5379, 2005